- In 2020, more than 495,000 adults globally received a diagnosis of pancreatic cancer.
- More than 90% of people with a common type of pancreatic cancer have KRAS mutations.
- Researchers discovered that certain KRAS mutations in pancreatic cancer are associated with better survival rates compared to other mutations in the disease.
- The findings add to existing research targeting KRAS mutations to develop a cancer vaccine.
In 2020,
In the United States, pancreatic cancer is the
Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer — accounting for about
Previous research shows that traditional cancer treatments such as
More than 90% of people with pancreatic cancer have mutations in their
Now researchers from The University of Texas MD Anderson Cancer Center have discovered that people with pancreatic cancer with certain types of
The study, recently published in the journal
Dr. Dan Zhao, researcher in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and co-lead author of this study explained to Medical News Today:
“Pancreatic ductal adenocarcinoma is projected to be the second leading cause of cancer death, but its treatment options remain limited. The 5-year overall survival rate for patients who have metastatic…
Read the full article here